Edesa Biotech, Inc. EDSA
2.00 USD -0.17 (-8.05%)
Regular-session close
1.99 -0.01 -0.50%
After hours · Nov 20, 4:00 PM ET
1.97 Day range 2.18
0.80 52-week range 18.28
- YTD
- +40.85%
- 1 year
- +15.61%
News
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 48.4% to $1.08 during Friday's pre-market session. The company's market cap stands at $4.1 million. Akanda (NASDAQ:AKAN) stock increased by…benzinga.com Edesa Biotech Receives European Commission Orphan Designation For Paridiprubart To Treat Acute Respiratory Distress Syndrome The designation follows a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products, recognizing both the high mortality rates in ARDS and the need for new…
globenewswire.com Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European Commission TORONTO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…benzinga.com Edesa Biotech Enters Collaboration And License Agreement With Kyorin Pharmaceutical For Paridiprubart In Japan; Deal Valued At $140M+ With Potential Milestone Payments Under the terms of the agreement, Kyorin will obtain an exclusive license to further develop and commercialize Edesa’s drug candidate, paridiprubart, in Japan, in Acute Respiratory Distress Syndrome…
